PRONTO-Peds

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with and Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes
To demonstrated that an ultra-fast-acting formulation of insulin lispro is non-inferior to Humalog on measures of glycemic control when administered 0 to 2 minutes before eating in combination with basal insulin.
CHLA IRB Number
CHLA-19-00158
Eligibility
Children between ages 1 to <18 years of age with an HbA1c ≥6.5% but ≤9.5%, not currently on an insulin pump, and willing to test between 4-7 times per day even if using CGM.
Clinical Trials Government Identifier
NCT03740919
Enrollment Status
Closed
Does this study also recruit healthy volunteers?
No
Coordinator Contact
Debra Miller
Contact Email

dmiller@chla.usc.edu